Seqirus, an Australian company focused in the influenza-virus vaccine segment and owned by CSL group, executed a contract with Verifarma for the serialization of its vaccines in Argentina.
The serialization and traceability of medicines was implemented in Argentina in 2011. For some time now, even more countries adopt regulations on the serialization of medicines with the purpose of eradicating counterfeiting.
Verifarma, has been implementing traceability of medicines for more than 12 years and offers services to more than 2000 companies in 20 countries around the world.
“We are delighted to be able to start this process for the serialization of medicines. Said process is part of our local consolidation plan which envisages also bringing innovation to the region. In this sense we are in the process of developing new products to launch them in the next few years and all of them will be serialized. We selected Verifarma due to its end-to-end serialization capacities, its after-market service and its local e international experience” informs Martín Rossini Head Of LatAm Operations of Seqirus.
On the other hand, Gabriel Silberleib, Business Manager of Verifarma for LATAM adds, “We are proud to be part of Seqirus’ serialization process in the country, especially in this context that stressed the importance of vaccines. We know that for the laboratories it is a path that involves effort. Our work is to accompany them so that the result may have the lesser impact possible in productivity and in the development of the business”.